Surf Wiki
Save to docs
general/mitotic-inhibitors

From Surf Wiki (app.surf) — the open knowledge base

Vinflunine

Chemical compound

Summary

Chemical compound

| Drugs.com =

| elimination_half-life =

Vinflunine (INN, trade name Javlor) is a novel fluorinated vinca alkaloid derivative undergoing research for the treatment of bladder cancer. It was originally discovered by the team of the Professor Jean-Claude Jacquesy (UMR CNRS 6514 – Poitiers University), developed by Laboratoires Pierre Fabre and was licensed to Bristol-Myers Squibb for development in certain countries, including the United States.

On November 23, 2007, Pierre Fabre Medicament and Bristol-Myers Squibb announced that they were terminating their license agreement for the development of vinflunine, and that Pierre Fabre were continuing "discussions with regulatory authorities and plan to file for the registration of vinflunine for bladder cancer in the first quarter of 2008."

Approvals and indications

, vinflunine was registered for use in Australia for "advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a prior platinum containing regimen," but is not covered under the Pharmaceutical Benefits Scheme.

, vinflunine was the only commercially-approved agent in some countries for salvage therapy of urothelial carcinoma, (with approval based on the results of a phase III trial), with a reported median OS of about 6 months.

Clinical trials

It has undergone a phase III clinical trial for advanced transitional cell carcinoma of the urothelial tract.

References

References

  1. "Javlor EPAR".
  2. (March 1998). "Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid". Biochemical Pharmacology.
  3. (1997). "''Vinca'' Alkaloids in Superacidic Media: A Method for Creating a New Family of Antitumor Derivatives". [[J. Am. Chem. Soc.]].
  4. (November 23, 2007). "Bristol-Myers Squibb and Pierre Fabre Provide Update On Vinflunine Development Status".
  5. (March 16, 2012). "Vinflunine, solution concentration for I.V. infusion, 50 mg in 2 mL and 250 mg in 10 mL (as ditartrate), Javlor® – November 2011". [[Pharmaceutical Benefits Scheme]].
  6. (June 2016). "Systemic Therapy for Urothelial Carcinoma: Is a Renaissance Around the Corner?". Oncology.
  7. (September 2009). "Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract". Journal of Clinical Oncology.
Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

mitotic-inhibitors indole-alkaloids quinoline-alkaloids drugs-developed-by-bristol-myers-squibb acetate-esters vinca-alkaloids methyl-esters
Want to explore this topic further?

Ask Mako anything about Vinflunine — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report